Merck & Co., Inc: all 2,453 studies
Page 2 of 25. Open to participants first (145), then studies with results posted, then the rest; newest registration first within each.
- A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)RecruitingNCT06731907Phase 2
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingNCT06717347Phase 3
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)RecruitingNCT06686394Phase 1/2
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)RecruitingNCT06667700Phase 3
- A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)RecruitingNCT06655883Phase 3
- A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).RecruitingNCT06655324Phase 1
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)RecruitingNCT06651281Phase 3
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)RecruitingNCT06623422Phase 3
- Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).RecruitingNCT06623409Phase 1
- A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisRecruitingNCT06559150Phase 2
- Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular DegenerationRecruitingNCT06487039Phase 2
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingNCT06469944Phase 1/2
- A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally AdvancedRecruitingNCT06467383
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)RecruitingNCT06445972Phase 1/2
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)RecruitingNCT06430801Phase 3
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)RecruitingNCT06428409Phase 1/2
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingNCT06422143Phase 3
- Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)RecruitingNCT06395103Phase 1/2
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)RecruitingNCT06393374Phase 3
- A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)RecruitingNCT06351631Phase 3
- A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)RecruitingNCT06345729Phase 3
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingNCT06312176Phase 3
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingNCT06312137Phase 3
- A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)RecruitingNCT06189391Phase 1
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RecruitingNCT06170788Phase 3
- A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)RecruitingNCT06163430Phase 1/2
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)RecruitingNCT06136650Phase 3
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)RecruitingNCT06136624Phase 3
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)RecruitingNCT06136559Phase 3
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).RecruitingNCT05947851Phase 3
- Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)RecruitingNCT05714085Phase 2/3
- Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)RecruitingNCT05587712Phase 2
- A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)RecruitingNCT05579132Phase 1/2
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Phase 1/2
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)RecruitingNCT05139017Phase 2/3
- Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)Not yet recruitingNCT05093972Phase 1
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)RecruitingNCT05067283Phase 1
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)RecruitingNCT04924075Phase 2
- Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)RecruitingNCT04728893Phase 2
- Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)RecruitingNCT04665037Phase 2
- Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)RecruitingNCT04375800Phase 2
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)RecruitingNCT04165798
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingNCT04165070Phase 1/2
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingNCT03486873Phase 3
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)RecruitingNCT02332668Phase 1/2
- A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or ObesityCompletedNCT06854952Phase 2Results posted
- A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)CompletedNCT06643377Phase 1Results posted
- A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)CompletedNCT06575959Phase 1Results posted
- A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPDCompletedNCT06545500Phase 2Results posted
- Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)CompletedNCT06482112Phase 2Results posted
- Effect of Ensifentrine Treatment on CAT ScoreCompletedNCT06460493Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)CompletedNCT06450366Phase 3Results posted
- A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)CompletedNCT06295796Phase 1Results posted
- Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)CompletedNCT06285240Phase 1Results posted
- A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)CompletedNCT06273774Phase 1Results posted
- Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)CompletedNCT06242691Phase 1/2Results posted
- A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan ExtensionActive, not recruitingNCT06212752Phase 3Results posted
- Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)TerminatedNCT06179407Phase 1Results posted
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)CompletedNCT06177912Phase 3Results posted
- Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)TerminatedNCT06161116Phase 2Results posted
- A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)TerminatedNCT06113328Phase 2Results posted
- A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)Active, not recruitingNCT06099782Phase 2Results posted
- A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)CompletedNCT06052566Phase 1Results posted
- Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)CompletedNCT06045507Phase 2Results posted
- A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)CompletedNCT05953740Phase 1Results posted
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)CompletedNCT05952869Phase 3Results posted
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef LipidsCompletedNCT05952856Phase 3Results posted
- Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)CompletedNCT05934292Phase 1Results posted
- A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)CompletedNCT05919693Phase 1/2Results posted
- A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)CompletedNCT05893862Phase 1Results posted
- A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)CompletedNCT05818137Phase 3Results posted
- Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)CompletedNCT05818124Phase 1Results posted
- Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)CompletedNCT05769595Phase 1Results posted
- A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)CompletedNCT05763823Phase 3Results posted
- A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)Active, not recruitingNCT05722015Phase 3Results posted
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)CompletedNCT05696080Phase 3Results posted
- A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)CompletedNCT05673460Phase 1Results posted
- A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)TerminatedNCT05665595Phase 3Results posted
- A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)CompletedNCT05656040Phase 1Results posted
- Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)CompletedNCT05633992Phase 3Results posted
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)Active, not recruitingNCT05631093Phase 3Results posted
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)Active, not recruitingNCT05630755Phase 3Results posted
- Study of CD388 Subcutaneous Administration in Healthy Japanese SubjectsCompletedNCT05619536Phase 1Results posted
- Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)TerminatedNCT05602727Phase 2Results posted
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension StudyCompletedNCT05600309Phase 3Results posted
- A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)CompletedNCT05594043Phase 1Results posted
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)CompletedNCT05569954Phase 3Results posted
- Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)CompletedNCT05559905Phase 2Results posted
- A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)CompletedNCT05558696Phase 2Results posted
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)CompletedNCT05526716Phase 3Results posted
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China ExtensionCompletedNCT05523323Phase 3Results posted
- The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy AdultsCompletedNCT05523089Phase 2Results posted
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)CompletedNCT05508867Phase 2Results posted
- Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)CompletedNCT05507450Phase 2Results posted
- MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)CompletedNCT05494736Phase 1Results posted
- A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)CompletedNCT05466422Phase 1Results posted
- A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)CompletedNCT05464420Phase 3Results posted
- Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)CompletedNCT05450198Phase 1Results posted
- Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)CompletedNCT05446870Phase 2Results posted
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)CompletedNCT05425732Phase 3Results posted